J O'Shaughnessy Selected Research

Estrogen Receptors

11/2017	Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
1/2016	Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

J O'Shaughnessy Research Topics

Disease

29	Breast Neoplasms (Breast Cancer) 05/2024 - 01/2000
8	Neoplasms (Cancer) 01/2021 - 12/2011
6	Triple Negative Breast Neoplasms 02/2024 - 08/2012
4	Disease Progression 05/2024 - 04/2015
2	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2018
1	Residual Neoplasm 02/2024
1	Cytopenia 01/2022
1	Second Primary Neoplasms (Neoplasms, Second) 01/2022
1	Retinoblastoma (Glioblastoma, Retinal) 01/2018
1	Hyperglycemia 01/2017
1	Nausea 01/2017
1	Diarrhea 01/2017
1	Alopecia (Baldness) 01/2017
1	Exanthema (Rash) 01/2017
1	Cardiotoxicity 10/2012
1	Proteinuria 05/2012
1	Left Ventricular Dysfunction 05/2012
1	Hypertension (High Blood Pressure) 05/2012
1	Neutropenia 06/2002
1	Hand-Foot Syndrome 02/2002
1	Enthesopathy 05/2001
1	Night Blindness (Nyctalopia) 01/2000

Drug/Important Bio-Agent (IBA)

7	Hormones (Hormone)IBA 01/2022 - 01/2018
5	Capecitabine (Xeloda)FDA Link 01/2021 - 02/2002
4	abemaciclibIBA 05/2024 - 12/2021
3	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 10/2012
3	ErbB Receptors (EGF Receptor)IBA 12/2021 - 01/2017
3	sacituzumab govitecanIBA 01/2021 - 12/2020
3	Letrozole (Femara)FDA LinkGeneric 11/2019 - 01/2016
3	ribociclibIBA 11/2019 - 01/2018
3	Bevacizumab (Avastin)FDA Link 01/2019 - 05/2012
3	Trastuzumab (Herceptin)FDA Link 01/2019 - 12/2011
3	Docetaxel (Taxotere)FDA Link 12/2013 - 09/2006
3	Tamoxifen FDA LinkGeneric 05/2001 - 01/2000
2	Aromatase InhibitorsIBA 05/2024 - 01/2016
2	pembrolizumabIBA 02/2024 - 01/2019
2	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 05/2001
2	Gemcitabine FDA Link 01/2021 - 01/2018
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 01/2017
2	taxaneIBA 01/2021 - 02/2002
2	Lapatinib (GW572016)FDA Link 01/2019 - 12/2011
2	exemestane (Aromasin)FDA Link 01/2018 - 01/2016
2	Anastrozole (Arimidex)FDA LinkGeneric 01/2018 - 01/2016
2	Estrogen ReceptorsIBA 11/2017 - 01/2016
2	AnthracyclinesIBA 03/2012 - 02/2002
1	Fulvestrant (Faslodex)FDA Link 05/2024
1	veliparibIBA 01/2022
1	Epidermal Growth Factor (EGF)IBA 01/2022
1	atezolizumabIBA 01/2021
1	eribulin FDA Link 01/2021
1	Albumin-Bound Paclitaxel FDA Link 01/2021
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2021
1	Vinorelbine (Navelbine)FDA LinkGeneric 01/2021
1	Surface Antigens (Surface Antigen)IBA 01/2021
1	Topoisomerase InhibitorsIBA 01/2021
1	B7-H1 AntigenIBA 01/2021
1	Cyclin D1IBA 01/2018
1	palbociclibIBA 01/2018
1	130-nm albumin-bound paclitaxelIBA 01/2018
1	Circulating Tumor DNAIBA 11/2017
1	NVP-BKM120IBA 01/2017
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2017
1	Abiraterone AcetateIBA 01/2016
1	Estrogens (Estrogen)FDA Link 01/2016
1	Androgen Receptors (Androgen Receptor)IBA 01/2016
1	Biosimilar PharmaceuticalsIBA 04/2015
1	HematinicsIBA 04/2015
1	liposomal doxorubicin (Doxil)FDA Link 10/2012
1	1-dodecylpyridoxal (PLD)IBA 10/2012
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2012
1	Monoclonal AntibodiesIBA 05/2012
1	human ERBB2 proteinIBA 12/2011
1	Taxoids (Taxanes)IBA 09/2006
1	Filgrastim (Neupogen)FDA Link 06/2002
1	pegfilgrastim (Neulasta)FDA Link 06/2002
1	Alitretinoin FDA Link 05/2001
1	HDL CholesterolIBA 05/2001
1	Vitamin A (Retinol)FDA LinkGeneric 01/2000
1	FenretinideIBA 01/2000
1	retinamideIBA 01/2000
1	RetinoidsIBA 01/2000

Therapy/Procedure

12	Therapeutics 05/2024 - 05/2001
11	Drug Therapy (Chemotherapy) 02/2024 - 01/2000
2	Neoadjuvant Therapy 02/2024 - 01/2022
1	Adjuvant Chemotherapy 01/2021
1	Drug Tapering 02/2002